FAKTOR OPTIONSSCHEIN - GENMAB | Real-time Boerse Frankfurt Warrants 12:20:54 20/06/2024 BST | ||
| 16.39 EUR | -5.48% |
|
| Current month | +44.14% | ||
| 1 month | +66.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 16.39 | -5.48% |
| 19/06/24 | 17.34 | +7.37% |
| 18/06/24 | 16.15 | -1.28% |
| 17/06/24 | 16.36 | +8.63% |
| 14/06/24 | 15.06 | -0.99% |
Real-time Boerse Frankfurt Warrants
Last update June 20, 2024 at 12:20 pm
More quotesStatic data
| Product type | Productos Exóticos |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
BNP Paribas
|
| WKN | PN4GMS |
| ISIN | DE000PN4GMS1 |
| Date issued | 10/11/2021 |
| Strike | 1,757 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 30 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 95.6 € |
|---|---|
| Lowest since issue | 4.54 € |
| Spread | 0.09 € |
| Spread % | 0.55% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,757
DKK
Average target price
2,464
DKK
Spread / Average Target
+40.24%
- Stock Market
- Certificates
- Certificat
